Lakefront Biotherapeutics NV
LKFT evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for LKFT—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · LKFT
Lakefront Biotherapeutics NV (LKFT) is a biotechnology company focused on identifying, acquiring, and advancing product candidates through a modality-agnostic, business-development-driven strategy, currently rebuilding its pipeline after winding down its cell therapy activities.
Key risk: Pipeline concentration risk
BioSniper Score
Based on 2 of 6 signals
Limited data coverage
Financial data as of Dec 31, 2025.
Tracking 29 clinical trials for Lakefront Biotherapeutics NV.
Lakefront Biotherapeutics NV (LKFT) is a biotechnology company focused on identifying, acquiring, and advancing product candidates through a modality-agnostic, business-development-driven strategy, currently rebuilding its pipeline after winding down its cell therapy activities.
- Cash and equivalents of $40.0M as of 2025-12-31 [sec].
- Total revenue of $1,112.2M and net income of $320.9M for the year ended 2025-12-31 [sec].
- Shareholders' equity of $2,896.9M and total debt of $17.8M as of 2025-12-31 [sec].
- Ongoing royalty streams and earn-outs from Jyseleca® expected to continue into the mid-2030s [sec · filed 2026-03-26].
- Only product candidate in development following the cell therapy wind-down is GLPG3667 [sec · filed 2026-03-26].
What works
- Strong financial foundation with significant cash reserves, ongoing royalty streams from Jyseleca®, and valuable assets including equity stakes in private biotech companies and real estate holdings [sec · filed 2026-03-26].
- Modality-agnostic asset selection approach and operational flexibility allow the company to pursue a range of transaction types from licensing to acquisitions [sec · filed 2026-03-26].
- Disciplined capital deployment strategy with a balanced risk profile, prioritizing late-stage development where potential impact is greatest [sec · filed 2026-03-26].
What to weigh
- Following the wind-down of cell therapy activities, the company has only one product candidate (GLPG3667) in development, making success heavily dependent on business development to rebuild the pipeline [sec · filed 2026-03-26].
- The company will require substantial additional future capital to acquire or develop product candidates and complete clinical development [sec · filed 2026-03-26].
- The wind-down of cell therapy activities is subject to various risks and uncertainties and may not be completed in a timely manner on favorable terms [sec · filed 2026-03-26].
- The biotechnology and pharmaceutical industries are intensely competitive, and failure to compete effectively could reduce commercial opportunities [sec · filed 2026-03-26].
From the filings
Quoted directly from source documents.
Ongoing royalty streams from Jyseleca® expected to continue into the mid-2030s
“Ongoing royalty streams and earn-outs from Jyseleca®, expected to continue into the mid-2030s.”
SEC filings · March 26, 2026
Company announced intention to wind down cell therapy activities in October 2025
“on October 21, 2025, we announced our intention to wind down our cell therapy activities and pursue new transformational business development transactions using our available cash resources.”
SEC filings · March 26, 2026
Risks & what to watch (4)›
Key risks
- Pipeline concentration risk — Only one product candidate (GLPG3667) in development after cell therapy wind-down; success depends on business development [sec · filed 2026-03-26].
- Need for substantial future capital — Requires additional capital to acquire or develop product candidates and complete clinical trials [sec · filed 2026-03-26].
- Cell therapy wind-down execution risk — Wind-down subject to risks and uncertainties; may not be completed on favorable terms or in a timely manner [sec · filed 2026-03-26].
- Intense industry competition — Biotech and pharma sectors are highly competitive; failure to compete could harm commercial prospects [sec · filed 2026-03-26].
What to watch
- Progress of business development efforts to acquire or partner new product candidates [sec · filed 2026-03-26].
- Completion of the cell therapy wind-down and associated costs and timeline [sec · filed 2026-03-26].
- Clinical development updates for GLPG3667, the sole remaining product candidate [sec · filed 2026-03-26].
- Continuation of royalty and earn-out payments from Jyseleca® into the mid-2030s [sec · filed 2026-03-26].
Sources: SEC filings · Generated August 25, 2026 · How we verify sources →
Run Lakefront Biotherapeutics NV through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Lakefront Biotherapeutics NV facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 2 of 6 signals · derived from public data
No clinical pipeline tracked — this score reflects financial & catalyst signals only.
11.1 months
D/E 0.05
No tracked pipeline phase
No tracked pipeline candidates
No upcoming catalysts tracked
No insider transactions in the last 180 days
Runway
Regulatory
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
85
Total value held
$814.8M
| Holder | Shares | Value |
|---|---|---|
| gilead sciences, inc. | 16,707,477 | $501.2M |
| tang capital management llc | 3,785,991 | $113.6M |
| prosight management, lp | 1,550,000 | $46.5M |
| ameriprise financial inc | 1,424,674 | $42.7M |
| segall bryant & hamill, llc | 854,498 | $26.7M |
| susquehanna international group, llp | 462,687 | $13.9M |
| renaissance technologies llc | 315,400 | $9.5M |
| blackrock, inc. | 312,106 | $9.4M |
| d. e. shaw & co., inc. | 215,718 | $6.5M |
| ubs group ag | 175,289 | $5.3M |
Showing top 10 of 85 institutional holders of Lakefront Biotherapeutics NV. Open the full 13F history after sign-in.
Short Interest
as of May 21, 2026- % of float
- 3.4%
- Days to cover
- 7.0
- Shares short
- 1,371,531
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
LKFT short interestGovernance
Frequently asked questions
What is the AI investment thesis for Lakefront Biotherapeutics NV?
Lakefront Biotherapeutics NV (LKFT) is a biotechnology company focused on identifying, acquiring, and advancing product candidates through a modality-agnostic, business-development-driven strategy, currently rebuilding its pipeline after winding down its cell therapy activities.
Who is the CEO of Lakefront Biotherapeutics NV?
Mr. Henry Gosebruch is the chief executive officer of Lakefront Biotherapeutics NV (LKFT).
Where is Lakefront Biotherapeutics NV headquartered?
Lakefront Biotherapeutics NV (LKFT) is headquartered in Mechelen, Belgium.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.